Kristen Coppock, MA

The FreeStyle Libre 2 iCGM aims to help patients with diabetes manage their condition and to share health data with care providers.

Abbott’s FreeStyle Libre 2 integrated continuous glucose monitoring (iCGM) systemis now available, according to the company.

The system is available by prescription at participating pharmacies and durable medical equipment suppliers across the United States.

The device was approved by the FDA in June 2020.1,2 It is indicated for adults and children ages 4 years and older with diabetes.

The FreeStyle Libre 2 next-generation sensor is worn on the back of the upper arm for 14 days is a third less bulky than other CGM sensors, according to Abbott. It allows patients with diabetes to view their glucose reading, trend arrow, and 8-hour history with a 1-second scan through a handheld reader.

This new system is designed to help people manage their condition, and it facilitates sharing health data with their doctors. According to Abbott, this technology is critical to achieving better outcomes and more efficient, safe telehealth visits.

Abbott is offering the new system at the same price as the previously made available FreeStyle Libre 14-day system, a cost that is about 70% less than other CGMs currently available, according to the company.

Murphy C. Abbott’s FreeStyle Libre 2 is Now Available. Abbott email. Sent July 30, 2020. Accessed August 4, 2020.

Coppock K. FDA Approves FreeStyle Libre 2 iCGM System for Patients With Diabetes. 

. pharmacytimes.com/news/fda-approves-freestyle-libre-2-icgm-system-for-patients-with-diabetes. Published June 15, 2020. Accessed August 4, 2020.

Articles

A new integrated continuous glucose monitoring system that aims to help patients with diabetes manage their condition and to share health data with care providers is now available.

New Integrated Continuous Glucose Monitor Available to Patients With Diabetes

has been released by the CDC’s Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP). The immunization schedules are revised annually with the most current recommendations for the use of

licensed by the US FDA, and changes are based on recommendations made by the ACIP in October.

2018 immunization schedule for children and teens

In the 2018 schedule for hepatitis B, information was added recommending that vaccination should be administered within 24 hours for infants with a birth weight of more than 2000g who are born to mothers that are negative for hepatitis B surface antigen. Updated recommendations have also been made for measles, mumps and rubella (MMR) vaccines.

The 2018 MMR schedule offers new guidance regarding use of a third dose of mumps-containing vaccine during a mumps outbreak.

Influenza wording was updated to indicate that live-attenuated influenza vaccine is not recommended for the 2017-2018 influenza season. The revised schedule for polio vaccines provides guidance for children who have received oral polio vaccine as part of their series. In addition, the inactivated poliovirus rows of the catch-up schedule was edited to clarify recommendations for children aged 4 and older.

Formatting revisions to the schedules also were made to the 2018 immunization schedules. They include the footnotes' incorporation of bullets and complete sentences, which are designed to increase the ease and clarity of all pertinent information.

On the title page, a new table shows common abbreviations and brand names for vaccines recommended for children and adolescents. Also, Figure 2 has been updated with a pair of changes, including the poliovirus amendment. In addition, the rotavirus vaccine row was revised to include the maximum ages for the first and last doses of the series.

In Figure 3, changes were made to the medical indications.

A reference providing additional information regarding HIV laboratory parameters and the use of live vaccines is provided in the HIV column. In the pneumococcal row, stippling was added to heart disease/chronic lung disease, chronic liver disease, and diabetes columns to clarify that children with these conditions may be recommended an additional dose of vaccine, in some situations.

1. American Academy of Pediatrics. Recommended Childhood and Adolescent Immunizaiton Schedules: United States, 2018.

http://pediatrics.aappublications.org/content/early/2018/02/02/peds.2018-0083

2. Centers for Disease Control and Prevention.

www.cdc.gov/vaccines/schedules/hcp/child-adolescent.html#changes

The updated 2018 immunization schedule for children and teens has been released by the Centers for Disease Control and Preventionâ€™s (CDCâ€™s) Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP). 

Kristen Coppock, MA

Articles

New Integrated Continuous Glucose Monitor Available to Patients With Diabetes

Revised 2018 Child and Adolescent Vaccine Schedule Released by ACIP